These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28588061)

  • 1. Dual HER2 Blockade Helps Prevent Breast Cancer Return.
    Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.
    Howie LJ; Scher NS; Amiri-Kordestani L; Zhang L; King-Kallimanis BL; Choudhry Y; Schroeder J; Goldberg KB; Kluetz PG; Ibrahim A; Sridhara R; Blumenthal GM; Pazdur R; Beaver JA
    Clin Cancer Res; 2019 May; 25(10):2949-2955. PubMed ID: 30552112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertuzumab and trastuzumab: the rationale way to synergy.
    Richard S; Selle F; Lotz JP; Khalil A; Gligorov J; Soares DG
    An Acad Bras Cienc; 2016; 88 Suppl 1():565-77. PubMed ID: 27275646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
    Eidtmann H
    Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
    [No Abstract]   [Full Text] [Related]  

  • 7. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-positive metastatic breast cancer: a changing scenario.
    Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis.
    Zambelli A; Pappagallo G; Marchetti P
    J Comp Eff Res; 2020 Apr; 9(6):423-430. PubMed ID: 32057255
    [No Abstract]   [Full Text] [Related]  

  • 10. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.
    Gerratana L; Bonotto M; Bozza C; Ongaro E; Fanotto V; Pelizzari G; Puglisi F
    Expert Opin Biol Ther; 2017 Mar; 17(3):365-374. PubMed ID: 28092723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.
    Gleeson JP; Keegan NM; Morris PG
    Expert Opin Biol Ther; 2018 Mar; 18(3):251-262. PubMed ID: 29183167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertuzumab: development beyond breast cancer.
    Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
    Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLEOPATRA holds strong in final analysis.
    Cancer Discov; 2014 Dec; 4(12):OF3. PubMed ID: 25477120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
    Baselga J; Swain SM
    Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
    Dawood S; Sirohi B
    Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
    Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
    Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual HER2 blockade slows metastatic breast cancer.
    Bender E
    Cancer Discov; 2012 Jan; 2(1):OF4. PubMed ID: 22585174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.